One may argue that longer periods of time have a greater potential of revealing reduction in neutrophil elastase activity in CF patients. Given the fact that PPL's clinical trials in CF started in December 1996, I believe the inhalation device, particle size and perhaps including patients with an extensive lungs and airway damage were major problems. On a side note: I'm guessing that GTCB is watching the Kamada inhaled trial and will push their own in case of Kamada's success. Comment?
Market Data 
Markets 
AI
